GSA Capital Partners’s Foghorn Therapeutics FHTX Stock Holding History
Bought
Maintained
Sold
Other funds holding FHTX
EC
SL
GSA Capital Partners's FHTX Position: Q3 2026 in Review
GSA Capital Partners increased its Foghorn Therapeutics (FHTX) stake by 132% in Q3 2026, buying an estimated $205K and bringing the position to 68,501 shares worth $245K. The position accounts for 0.01% of the portfolio, ranked #1498.
GSA Capital Partners first reported a position in FHTX in Q4 2023 and has held it in 4 quarters since. The position peaked at $266K in Q4 2023. 122 funds tracked by Wall St. Rank hold FHTX as of Q3 2026.
- GSA Capital Partners held 68,501 shares of Foghorn Therapeutics worth $245K as of Q3 2026.
- GSA Capital Partners bought 38,995 Foghorn Therapeutics shares in Q3 2026, an estimated $205K.
- Foghorn Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q3 2026, its #1498 holding.
- GSA Capital Partners first reported a position in Foghorn Therapeutics in Q4 2023 and has held it in 4 quarters since.
- GSA Capital Partners's Foghorn Therapeutics position peaked at $266K in Q4 2023.
- 122 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2026.
Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.